CoChat

The nocebo effect challenges the non-medical infliximab switch in practice

Open access
Boone, N. W., Liu, L., Romberg-Camps, M. J., Duijsens, L., Houwen, C., van der Kuy, P. H. M., Janknegt, R., Peeters, R., Landewé, R. B. M., Winkens, B., van Bodegraven, A. A. · 2018 · European Journal of Clinical Pharmacology
Cited by 118

The DOI matches its Crossref record.

Abstract

BACKGROUND: In clinical practice, non-medical switching of biological medication may provoke nocebo effects due to unexplained deterioration of therapeutic benefits. Indication extrapolation, idiosyncratic reactions, and interchangeability remain challenged in clinical practice after biosimilar approval by the European Medicines Agency. The principle of "first do no harm" may be challenged in a patient when switching from originator to biosimilar biological. AIM: To describe the 1-year results of a pragmatic study on infliximab biosimilar implementation in immune-mediated inflammatory disease patients on the basis of shared decision-making under effectiveness and safety monitoring. METHODS: Inflammatory bowel disease and rheumatology patients on infliximab originator were converted to infliximab biosimilar after providing informed consent. Nocebo response patients were monitored after switch back to originator. Linear mixed models were used to analyze continuous endpoints on effectiveness and laboratory outcomes to determine significance (P ≤ 0.05) of change over time after switching. RESULTS: After inviting 146 patients, a group of 125 patients enrolled in the project over time, respectively, 73 Crohn's disease, 28 ulcerative colitis, nine rheumatoid arthritis, ten psoriatic arthritis, and five ankylosing spondylitis patients. No statistically significant changes in effectiveness and safety were observed in any of the indications after a median of 4 infusions in 9 months of study. An overall nocebo response of 12.8% was found among the patients during a minimal observation period of 6 months after the transition to biosimilar infliximab. The overall nocebo response rate did not differ between the studied indications. CONCLUSIONS: In inflammatory bowel disease and rheumatological patients, similar effectiveness and safety were demonstrated on the transition into infliximab biosimilar. In our series, patient empowerment and registration of treatment outcomes delineated biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for regarding biosimilar implementation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00228-018-2418-4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 118

Metadata

Authors
Boone, N. W., Liu, L., Romberg-Camps, M. J., Duijsens, L., Houwen, C., van der Kuy, P. H. M., Janknegt, R., Peeters, R., Landewé, R. B. M., Winkens, B., & van Bodegraven, A. A.
Venue
European Journal of Clinical Pharmacology
Published
2018-01-24
Volume
74
Issue
5
Pages
655-661
ISSN
  • 0031-6970 (ISSN-L)
  • 1432-1041
OpenAlex
W2784409714
Cited by
118
References
0
FWCI
6.98
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The nocebo effect challenges the non-medical infliximab switch in practice. https://app.cochat.ai/papers/10.1007/s00228-018-2418-4
The paper
Boone, N. W., Liu, L., Romberg-Camps, M. J., Duijsens, L., Houwen, C., van der Kuy, P. H. M., Janknegt, R., Peeters, R., Landewé, R. B. M., Winkens, B., & van Bodegraven, A. A. (2018). The nocebo effect challenges the non-medical infliximab switch in practice. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-018-2418-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.